Emerging retatrutide, a combined-action medication targeting simultaneously GLP-1 and GIP receptors, is sparking considerable excitement within the healthcare community. Initial clinical trials have shown impressive decreases in overall size and improvements in physiological markers for individuals with obesity . Experts believe this ground-brea… Read More